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Abstract
Background: There is currently no formal method for predicting the range
expected in an individual’s seizure counts. Having access to such a prediction
would be of benefit for developing more efficient clinical trials, but also for
improving clinical care in the outpatient setting. Methods: Using three inde-
pendently collected patient diary datasets, we explored the predictability of sei-
zure frequency. Three independent seizure diary databases were explored:
SeizureTracker (n = 3016), Human Epilepsy Project (n = 93), and NeuroVista
(n = 15). First, the relationship between mean and standard deviation in seizure
frequency was assessed. Using that relationship, a prediction for the range of
possible seizure frequencies was compared with a traditional prediction scheme
commonly used in clinical trials. A validation dataset was obtained from a sepa-
rate data export of SeizureTracker to further verify the predictions. Results: A
consistent mathematical relationship was observed across datasets. The loga-
rithm of the average seizure count was linearly related to the logarithm of the
standard deviation with a high correlation (R2 > 0.83). The three datasets
showed high predictive accuracy for this log–log relationship of 94%, compared
with a predictive accuracy of 77% for a traditional prediction scheme. The
independent validation set showed that the log–log predicted 94% of the cor-
rect ranges while the RR50 predicted 77%. Conclusion: Reliably predicting sei-
zure frequency variability is straightforward based on knowledge of mean
seizure frequency, across several datasets. With further study, this may help to
increase the power of RCTs, and guide clinical practice.
Key Points
• The variance of seizure frequency is predictable across
diverse data.
• The logarithm of the average seizure count is highly
correlated with the logarithm of the standard deviation.
• In the future, these predictions may be built into clini-
cal trial analysis, and into clinical practice.
Introduction
Clinical trials in epilepsy have suffered from steadily ris-
ing placebo response rates over the past several decades1
typically ranging 4–27%2 but recently reaching as high as
40%.3 This can translate into unsuccessful trials, and sub-
sequent increasing trial development costs.4 Natural vari-
ability in seizure frequency is a relatively unmeasured
quantity. However, it may explain a portion of the “pla-
cebo effect” in epilepsy trials.5 Gaps in knowledge about
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this variability hampers interpretation of any randomized
clinical trial (RCT) that bases the outcome on seizure fre-
quency changes. The 50%-responder rate, the preferred
outcome measure of the European Medicines Agency, was
selected because it is clinically relevant. However, because
of the natural variability in seizure frequencies, subjects in
the placebo arm may be misidentified as “responders”.
Simulations based on 1767 patient seizure diaries showed
that many 50%-responders in RCTs may subsequently
become nonresponders (and perhaps subsequently again
become responders) due to natural variability.5 This sug-
gests that using the 50%-responder rate to measure “im-
provement” is confounded by the noise of natural
variability. The signal-to-noise ratio of improvement ver-
sus natural variability is likely to be lower than desired
for cost-effective RCT implementation. Understanding the
expected variability in seizure rates would be of great
value in improving interpretability, generalizability, and
efficiency of epilepsy RCTs.
Standard clinical practice requires an implicit judgment
about natural variability. Specifically, physicians make
medication regimen changes based on whether a patient’s
typical seizure rate has worsened above an expected upper
bound on seizure frequency (decided based on clinical
experience). Moreover, if a new drug adjustment results
in seizure reduction below an expected rate (again
decided based on clinical experience), the adjustment is
considered beneficial. Therefore, any perceived drug
effects are based on an implicit accounting for natural
variability. For patients that achieve long-term seizure-
freedom, such calculations are unnecessary. But if the sei-
zure-freedom is short-lived, measured over a short dura-
tion, or in the absence of seizure-freedom, these
calculations are currently left to the intuitive decision-
making of individual practitioners, as no formal clinical
tools exists.
Clinicians and trialists may benefit from a robust
method for measuring/predicting the extent of the seizure
rates based on natural variability. This study represents
the first attempt to predict the variance of seizure fre-
quency measurements, using a multi-modal data-driven
approach.
Methods
Data
The data came from three independently collected patient
diary databases (Table 1). Each dataset was managed in
deidentified format, consistent with the recommendations
of the NIH Office of Human Subject Research Protec-
tions, Protocol #12301. For each dataset, the data were
redacted into diary format. The patients were not
required to have fixed, unchanging medication regimens.
In fact, some patients changed their medications often,
while others did not. In the case of SeizureTracker, the
medication change data was sufficiently incomplete that
it was not evaluated. These diverse data provided a
robust basis for our investigation into seizure rate vari-
ability, and provided confidence in the generalizability of
results.
Data were obtained from a study (NeuroVista) in
which subdural electrodes were chronically implanted in
an attempt to provide patients with a seizure warning
system.6 Although only 15 patients were enrolled in
that study, it represents one of the most completely
characterized longitudinal seizure datasets available. All
patients were adults with confirmed focal epilepsy. The
data consisted of several types of seizures: type 1, which
were clinical seizures (reported or confirmed to be
clinical by audio review) that had electrographic
correlation; type 2, unconfirmed clinical (unreported)
seizures with electrographic pattern identical to type 1;
and type 3, subclinical, nonreported seizures with elec-
trographic patterns that differed from types 1 and 2.
Patients maintained implants for 7–24 months (median
12).
A second dataset was obtained from the Human Epi-
lepsy Project (HEP),7 which is an ongoing multicenter
study based on a highly screened set of adult patients
with focal epilepsy who are enrolled early in their diagno-
sis, and has very complete data recording including self-
reported data quality measures. Data included all 263
patients from July 2012 to March 2016. This dataset rep-
resents the one of the most reliable patient-reported
Table 1. Data sets. Shown here are the three datasets used for testing Model V and Model F (NeuroVista, HEP, and SeizureTracker), as well as
the additional dataset (denoted with *) from SeizureTracker used in the validation simulation.
N
N (after
exclusions)
Study duration
in months (median)
Diary durations
after exclusion criteria Ages Epilepsy
NeuroVista 15 15 7–24 (12) 7–24 (12) Adults Focal
Human Epilepsy Project 263 93 1–46 (16) 8–42 (22) Adults Focal
SeizureTracker.com 12946 3016 0–596 (1) 6–596 (20) Adults + children Focal and generalized
SeizureTracker.com (*) 1835 403 0–8 (3) 6–8 (8) Adults + children Focal and generalized
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seizure databases available, because of the extensive physi-
cian oversight and independent verification of diagnosis
and data quality. Diary data for each patient tracked 1–
46 months of data (median 16).
A third dataset was obtained from SeizureTracker.c
om,8 an online and mobile free service, representing one
of the world’s largest patient managed seizure diary data-
bases. Of note, the patients in this database have focal or
generalized epilepsy, and include adults and children. The
SeizureTracker database consisted of a data export of all
consecutive data entered from the project start in Decem-
ber 2007 through October 2015, comprising 12,946
patients and 1,060,680 seizures. A second export of Sei-
zureTracker from October 2015 through May 2016 was
obtained for a validation stage see Section 2.5 below add-
ing 149,356 new seizures from 1835 patients (846 of
which were new patients).
Preprocessing
To compute longitudinal predictions of seizure frequency
(Mean and variance of seizure frequency), some prepro-
cessing was required to ensure that there was both suffi-
cient data to study, and an adequate signal-to-noise ratio.
In all three datasets, we required each patient to have at
least 6 months of diary data and, independently, at least
six seizures recorded to be included for further analysis
(see Table 1). This minimum duration was selected based
on the fact that simulations were standardized to
6 months in duration.
The SeizureTracker data required additional prepro-
cessing to reduce noise, as there was no physician curat-
ing the data. Repeated patient profiles were removed.
Patients with unreported or impossible ages were
excluded. Seizures reported to occur after the export dates
were excluded. Seizures reported with identical start times
were removed except for the first one, under the assump-
tion that these represented erroneous repeat entries. Sei-
zures erroneously reported to occur prior to patients’
date of birth were excluded.
Mean and variance of seizure frequency
We explored the 2-week seizure frequencies of individ-
ual patients. Because seizures are very rapid events typi-
cally lasting less than two minutes,9 truncation of
events at the edges of 2-week segments was considered
unnecessary. All available 2-week segments were
included in these calculations. Thus, for the jth patient,
the mean (lj) and standard deviation (rj) were com-
puted across all M available 2-week segments. For the
ith segment in the jth patient, the 2-week seizure count
was given by Ci,j:
lj ¼
1
M
XM
i¼1
Ci;j (1)
rj ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
M  1
XM
i¼1
ðCi;j  ljÞ2
vuut (2)
To account for the wide range of seizure rates, we
applied a base-10 logarithmic transform to both lj and
rj.
yj ¼ log10 rj
 
(3)
xj ¼ log10 lj
 
(4)
We plotted the transformed mean versus the trans-
formed standard deviation for each patient’s seizure rates.
A linear regression line was fit through the set of all
patients from each dataset, with 95%-confidence regions
as well. The coefficient of determination (R2) and coeffi-
cient estimates (m and b) were reported for each dataset:
yj ¼ mxj þ b (5)
Predicting seizure counts using the log–log
plot, the “L relationship”
With a given average seizure frequency (lj), one could
use Equations 1–5 to predict the standard deviation (r)
with the “L relationship”:
rj ¼ 10mlog10 ljð Þþb (6)
To test the accuracy of such predictions, we divided
each patient’s diary into 6-month segments to represent a
typical clinical trial of 2-months baseline, 1-month
titration, and 3-months experimental period. For each 6-
month segment, the 2-month “baseline” was used to
estimate lj with Equation 1.
Two approaches for seizure frequency range predictions
were tested on the individual patient level: the 50%-
responder rate (RR50) method and the L method. For the
L method, the 95%-confidence limits of expected experi-
mental Ci,j rates were computed using measured l and
Equation 6 predicted r:
Ci;j 2 lj  2rj; lj þ 2rj
h i
(7)
The RR50 model has been required by the EMA for
traditional epilepsy RCTs, and therefore has been
employed for many years. It makes no assumptions about
the distribution (unlike the Gaussian assumption of the L
model). Rather, it only specifies the lower limit of the 2-
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week counts during the experimental phase from the jth
patient (Ci,j) as follows:
Ci;j 2 0:5lj; 1
h 
(8)
Results
Of the available 12,949 patients in the first SeizureTracker
export with at least one seizure recorded, preprocessing
decreased this to 11,736. Then 5938 remained after
requiring six or more seizures, and 3016 patients were
retained after requiring 6 months or longer diaries. Of
the 263 patients from HEP, 107 had six or more seizures,
and of those, 93 had 6 months or longer recorded. All 15
NeuroVista patients were included.
The plots relating average 2-week seizure frequency to
standard deviation (the square root of variance) from
both patient-reported datasets (SeizureTracker and HEP)
and the confirmed clinical (type 1) seizures from intracra-
nial recordings (NeuroVista) superimposed are shown in
Figure 1A, with linear fit lines. The three forms of Neuro-
Vista seizures are shown in Figure 1B. Note that each
point in Figure 1 represents the entire diary of an indi-
vidual. Although coming from very different sources, all
the log-transformed data followed a consistent linear rela-
tionship with a high coefficient of determination (0.827–
0.971). Notably, all the fit lines overlapped, suggesting a
common trend across otherwise disparate datasets. Using
the results of Figure 1, we selected m = 0.7 and
b = 0.0097 for Equations 5 and 6.
The validation data export of SeizureTracker included
1835 patients, of which 403 patients met inclusion crite-
ria. A plot of the prediction accuracy of the ranges from
the two methods is shown in Figure 2. The accuracy of
the log–log relation ranged from 96–100%, while the
RR50 method yielded 42–70% accuracy. In the validation
dataset, the log–log predicted 94% of the correct ranges
while the RR50 predicted 77%.
Discussion
Our study found evidence that changes in seizure fre-
quency could be accounted for with high accuracy using
a Gaussian model coupled to a non-linear predictor.
The predictor was generated based on a consistent
relationship noted across three independent datasets.
Future work could lead to broader implications: smaller
and less expensive clinical trials, and improved clinical
care models.10
Advantages of variance prediction
Current epilepsy RCTs assume that any reduction in
baseline seizure rate below 50% represents an improve-
ment. This implies a linear relationship between the
expected range and average seizure frequency (Equa-
tion 8). Our investigation of three independent datasets
(Fig. 1) found that a non-linear relationship (Equa-
tions 1–7) is more appropriate. Correcting for these
expected levels of variability may increase statistical
Figure 1. Log–log plot of seizure frequency mean and standard deviation (the square root of variance) for each patient. Each patient is
represented by a single point on this plot. Linear fit lines (with confidence regions) are drawn for each of the datasets. A: Representative datasets:
the clinically reported and verified seizures (subtype 1) of NeuroVista, the HEP data, and the SeizureTracker data. B: The three subtypes of
NeuroVista, plotted in the same way as A. These plots were used to develop the predictions in Equation 6.
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efficiency of clinical trials, thereby reducing costs. One
example use would be to integrate these variability pre-
dictions as an extension to the therapeutic intensive sei-
zure analysis method (TISA), allowing for more nuanced
statistical analysis with small numbers of patients, brief
trial duration and objective seizure recording meth-
ods.11,12 More broadly, these variability corrections could
be built into a trial analysis calculation, similar to the
recently reported ZV method.
10
In the outpatient clinic, physicians treating patients
with different baseline seizure frequencies can quantita-
tively anticipate natural fluctuations in seizure frequency,
and thereby evaluate treatment with greater confidence.
An explicit account of expected variance will ensure
patients and clinicians do not respond precipitously to
“changes” in seizure frequency. In addition, the over-
whelming consistency of the log-linear relationship across
patients indicates that a single estimate of the patient’s
seizure-frequency is all that is required to obtain the pre-
dicted variance of their seizure rates. Therefore, very little
baseline data is required to apply our model for seizure
variability on a patient-specific basis. Furthermore, the
model L calculation can be computed easily in the clinic,
on a mobile app, or within modern electronic medical
record systems. Although not currently available clinically,
future work will explore this possibility.
Limitations of the prediction model
The model has some hidden assumptions that require
consideration. First, it assumes that the relationship
between seizure frequency and variance is predictable.
Despite the reproducibility across datasets and the valida-
tion dataset, the possibility remains that these findings
will not fully generalize across all forms of epilepsy and in
all circumstances. Second, it assumes that the baseline
measurement is sufficient to obtain an estimate of the
true average seizure frequency. This estimate is imprecise;
therefore, the question of how much uncertainty in esti-
mated seizure frequency can be tolerated by the model
should be a topic for future investigation. The fact that
predictions of future seizure variability were accurate
(Fig. 2), indicate that the degree of precision in the base-
line estimate may be sufficient.
An additional limitation related to the nature of the
data we evaluated should be considered. Given that we
required patients to have six or more seizures recorded
during six or more months, we were excluding those
patients that have very few lifetime seizures. Moreover, it
is well-recognized that datasets that describe very infre-
quent seizures are not currently available. As a result of
these concerns, it is possible that the log–log relationship
described in this study may not relate to patients with
Figure 2. Predictions from the 50%-responder (RR50) method (Equation 8) and log–log method (Equation 7), applied to multiple datasets to
estimate the range of possible seizure frequencies. If a seizure frequency was within the predicted range, then it was scored as correct. ST (old) is
the large SeizureTracker dataset used in Figure 1. ST (new) is the independent validation dataset not included in the exploratory analysis from
Figure 1. Broadly speaking, the log–log predictions had considerably more accuracy than the RR50 predictions across all datasets assessed.
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very few lifetime seizures or very infrequent seizures. The
results are expected to be biased toward patients more
likely to be drug resistant. As well treated patients change
from a state of having many seizures to extremely few or
none, it is unknown if the log–log relationship would be
meaningful after that transition.
Data considerations
One of the most compelling points of the results we have
presented was their consistency, despite the fact that the
three datasets used in this study were from diverse
sources. The NeuroVista data was derived from very few
patients with medication resistant focal epilepsy, whereas
the other two datasets included focal and generalized
forms of epilepsy. One of the key strengths of NeuroVista
is that the data can be considered gold standard in terms
of reliability of seizure detection, since intracranial elec-
trodes were used to identify and characterize each seizure.
The HEP dataset requires that patients enroll early in
their diagnosis of epilepsy, whereas the other two do not.
HEP data was composed of patient reported outcomes.
Nevertheless, it had the most detailed mechanisms in
place for multiple physicians reviewing clinical data,
ensuring reliability. The SeizureTracker dataset includes
longitudinal data that spans many years and more
patients than most existing datasets in the world, while
the other two are more restricted. The SeizureTracker
dataset is the only one of the three that does not have
physician oversight to ensure data reliability. Despite
these various differences, a number of common results
emerged, which strengthen the claims that these findings
are generalizable.
Unlike HEP and NeuroVista, SeizureTracker data has
additional biases inherent in any self-reported patient data-
base lacking physician oversight.8 Perhaps the most chal-
lenging is “diary fatigue,” that is, the gradual or abrupt
disuse of the diary because the patient or caregiver loses
interest. There is no straightforward correction available.
SeizureTracker also was unique among the three datasets
because of the population studied. That data uniquely
included children and generalized forms of epilepsy, neither
of which were included in the other two datasets. To over-
come this and other biases, we have studied HEP and Neu-
roVista that both had considerable physician oversight, and
found the results were consistent across each.
An important consideration, particularly relevant to the
HEP dataset, though at least partially relevant to all of
them, is the possibility of medication changes influencing
seizure frequencies and variability. HEP is unique here:
because these patients were recently diagnosed with epi-
lepsy, they would be expected to have more frequent
medication changes than some other populations.
Although this effect may certainly influence the outcome
of the predictions, adjusting for this would be expected to
only improve the estimations further. Thus, unadjusted
values are presented here as a lower bound for the possi-
bility of prediction.
It is clinically challenging to determine if a patient has
failed a treatment. For instance, after taking drug X for
3 months, a patient that had a single breakthrough sei-
zure may reasonably ask their doctor, “should I stop this
drug? It doesn’t seem to work.” The methodology
described in this study will not clearly answer questions
of this variety, because seizure-freedom is not sufficiently
sampled with the data considered here. By the same
token, patients who have extended seizure-free periods
for many months with a single breakthrough seizure
would not benefit from the present analysis, as no mean-
ingful prediction could be made for them. Conversely,
patients that are drug-resistant that have relative decreases
or increases in their “usual” seizure frequency may benefit
from this type of analysis because it may allow for a more
structured approach to determining what is, and what is
not, a change. As more comprehensive datasets become
available, the breadth with which this type of analysis
would apply could expand.
Conclusions
This study represents the first formal attempt to quantify
the relationship between average seizure frequency and
variability. The findings presented here suggest that the
new L technique has the potential to improve the power
and efficiency of RCTs. Further investigation is required
to validate this possibility. In the future, this could
improve the safety of patients via decreased exposure to
nontherapeutic doses of medications.13 Indeed, smaller,
more efficient trials could lead to much lower drug trial
costs, thereby accelerating drug discovery.
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